Targeting mitogen-activated protein Kinase Kinase with the inhibitor pd0325901 decreases hepatocellular carcinoma growth in vitro and in mouse model systems

Hepatology

Volumn 51, Issue 4, 2010, Pages 1218-1225

  Hennig, Matthew ^a   Yip Schneider, Michele T ^a   Wentz, Sabrina ^a   Wu, Huangbing ^a   Hekmatyar, S K ^b   Klein, Patrick ^a   Bansal, Navin ^c,e   Max Schmidt, C ^a,d  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c INDIANA UNIVERSITY   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e RICHARD L ROUDEBUSH VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE KINASE; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; TRANSFORMING GROWTH FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CELL STRAIN HEPG2; CONTROLLED STUDY; ENZYME ACTIVITY; GROWTH RATE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN TARGETING; TRANSGENIC MOUSE;

ANIMALS; APOPTOSIS; BENZAMIDES; CELL PROLIFERATION; DIPHENYLAMINE; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, TRANSGENIC; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77950603104     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.23470     Document Type: Article

References (36)

1. El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004;127:S27-S34.
2. Carr BI. Hepatocellular carcinoma: current management and future trends. Gastroenterology 2004;127:S218-S224.
3. Duffy JP, Hiatt JR, Busuttil RW. Surgical resection of hepatocellular carcinoma. Cancer J 2008;14:100-110.
4. Uenishi T, Hirohashi K, Shuto T, Kubo S, Tanaka H, Sakata C, et al. The clinical significance of lymph node metastases in patients undergoing surgery for hepatocellular carcinoma. Surg Today 2000;30:892-895.
5. Bruix J, Castells A, Bosch J, Feu F, Fuster J, Garcia-Pagan JC, et al. Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology 1996;111:1018-1022.
6. Kosuge T. Surgical treatment of hepatocellular carcinoma. Princess Taka-matsu Symp 1995;25:265-270.
7. Thuluvath PJ, Maheshwari A, Thuluvath NP, Nguyen GC, Segev DL. Survival after liver transplantation for hepatocellular carcinoma in the model for end-stage liver disease and pre-model for end-stage liver disease eras and the independent impact of hepatitis C virus. Liver Transpl 2009; 15:754-762.
8. Lai CL, Wu PC, Chan GC, Lok AS, Lin HJ. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma: a prospective randomized trial. Cancer 1988;62:479-483.
9. Cormier JN, Thomas KT, Chari RS, Pinson CW. Management of hepa-tocellular carcinoma. J Gastrointest Surg 2006;10:761-780.
10. Mathurin P, Raynard B, Dharancy S, Kirzin S, Fallik D, Pruvot FR, et al. Meta-analysis: evaluation of adjuvant therapy after curative liver resection for hepatocellular carcinoma. Aliment Pharmacol Ther 2003;17:1247-1261.
11. Mendizabal M, Reddy KR. Current management of hepatocellular carcinoma. Med Clin North Am 2009;93:885-900, viii.
12. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359: 378-390.
13. McKillop IH, Schmidt CM, Cahill PA, Sitzmann JV. Altered expression of mitogen-activated protein kinases in a rat model of experimental hepato-cellular carcinoma. HEPATOLOGY 1997;26:1484-1491.
14. Osada S, Kanematsu M, Imai H, Goshima S, Sugiyama Y. Evaluation of extracellular signal regulated kinase expression and its relation to treatment of hepatocellular carcinoma. J Am Coll Surg 2005;201:405-411.
15. Schmidt CM, McKillop IH, Cahill PA, Sitzmann JV. Increased MAPK expression and activity in primary human hepatocellular carcinoma. Bio-chem Biophys Res Commun 1997;236:54-58.
16. Tsuboi Y, Ichida T, Sugitani S, Genda T, Inayoshi J, Takamura M, et al. Overexpression of extracellular signal-regulated protein kinase and its correlation with proliferation in human hepatocellular carcinoma. Liver Int 2004;24:432-436.
17. Guan KL. The mitogen activated protein kinase signal transduction pathway: from the cell surface to the nucleus. Cell Signal 1994;6:581-589.
18. Calvisi DF, Thorgeirsson SS. Molecular mechanisms of hepatocarcinogen- esis in transgenic mouse models of liver cancer. Toxicol Pathol 2005;33: 181-184.
19. Chung YH, Kim JA, Song BC, Lee GC, Koh MS, Lee YS, et al. Expression of transforming growth factor-alpha mRNA in livers of patients with chronic viral hepatitis and hepatocellular carcinoma. Cancer 2000;89:977-982.
20. Nalesnik MA, Lee RG, Carr BI. Transforming growth factor alpha (TG-Falpha) in hepatocellular carcinomas and adjacent hepatic parenchyma. Hum Pathol 1998;29:228-234.
21. Sohda T, Iwata K, Tsutsu N, Kamimura S, Shijo H, Sakisaka S. Increased expression of transforming growth factor-alpha in a patient with recurrent hepatocellular carcinoma following partial hepatectomy. Pathology 2001; 33:511-514.
22. Vail ME, Pierce RH, Fausto N. Bcl-2 delays and alters hepatic carcinogen-esis induced by transforming growth factor alpha. Cancer Res 2001;61: 594-601.
23. Zhang J, Wang WL, Li Q, Qiao Q. Expression of transforming growth factor-alpha and hepatitis B surface antigen in human hepatocellular carcinoma tissues and its significance. World J Gastroenterol 2004;10:830-833.
24. Prenzel N, Fischer OM, Streit S, Hart S, Ullrich A. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer 2001;8:11-31.
25. Sato Y, Kato J, Takimoto R, Takada K, Kawano Y, Miyanishi K, et al. Hepatitis C virus core protein promotes proliferation of human hepatoma cells through enhancement of transforming growth factor alpha expression via activation of nuclear factor-kappaB. Gut 2006;55:1801-1808.
26. Thoresen GH, Guren TK, Sandnes D, Peak M, Agius L, Christoffersen T. Response to transforming growth factor alpha (TGFalpha) and epidermal growth factor (EGF) in hepatocytes: lower EGF receptor affinity of TGFalpha is associated with more sustained activation of p42/p44 mito-gen-activated protein kinase and greater efficacy in stimulation of DNA synthesis. J Cell Physiol 1998;175:10-18.
27. Wiesenauer CA, Yip-Schneider MT, Wang Y, Schmidt CM. Multiple anticancer effects of blocking MEK-ERK signaling in hepatocellular carcinoma. J Am Coll Surg 2004;198:410-421.
28. Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 2004;4:937-947.
29. Klein PJ, Schmidt CM, Wiesenauer CA, Choi JN, Gage EA, Yip-Schneider MT, et al. The effects of a novel MEK inhibitor PD184161 on MEK-ERK signaling and growth in human liver cancer. Neoplasia 2006;8:1-8.
30. Yip-Schneider MT, Klein PJ, Wentz SC, Zeni A, Menze A, Schmidt CM. Resistance to MEK inhibitors correlates with upregulation of the MEK/ ERK pathway in hepatocellular carcinoma cells. J Pharmacol Exp Ther 2009;329:1063-1070.
31. Takagi H, Sharp R, Hammermeister C, Goodrow T, Bradley MO, Fausto N, et al. Molecular and genetic analysis of liver oncogenesis in transforming growth factor alpha transgenic mice. Cancer Res 1992;52:5171-5177.
32. Lee GH, Merlino G, Fausto N. Development of liver tumors in transforming growth factor alpha transgenic mice. Cancer Res 1992;52:5162-5170.
33. Hufnagl K, Parzefall W, Marian B, Kafer M, Bukowska K, Schulte-Her-mann R, et al. Roleof transforming growth factor alpha and prostaglandins in preferential growth of preneoplastic rat hepatocytes. Carcinogenesis 2001;22:1247-1256.
34. Schaff Z, Hsia CC, Sarosi I, Tabor E. Overexpression of transforming growth factor-alpha in hepatocellular carcinoma and focal nodular hyper-plasia from European patients. Hum Pathol 1994;25:644-651.
35. Yeh YC, Tsai JF, Chuang LY, Yeh HW, Tsai JH, Florine DL, et al. Elevation of transforming growth factor alpha and its relationship to the epidermal growth factor and alpha-fetoprotein levels in patients with hep-atocellular carcinoma. Cancer Res 1987;47:896-901.
36. Wentz SC, Wu H, Yip-Schneider MT, Hennig M, Klein PJ, Sebolt-Leopold J, et al. Targeting MEK is effective chemoprevention of hepato-cellular carcinoma in TGF-alpha-transgenic mice. J Gastrointest Surg 2008;12:30-37.